Recent studies have shown that in EGFR-mutant non-small cell lung cancer (NSCLC), resistance to tyrosine kinase inhibitors (TKIs) often involves increased PI3K signalling, which promotes cell survival independent of EGFR activation [67]. Here, EGFR is linked to non-small cell lung carcinoma.